Figure 2.
Probability of dose reduction as a function of time (in days) between the first treatment cycle and first reassessment for oxaliplatin (a), irinotecan (b), 5FU bolus (c), and 5FU continuous infusion (d).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.